Novavax files for COVID-19 vaccine approval in Canada
Novavax announced Monday in a news release that it had completed a rolling submission to Health Canada for authorization of its two-dose COVID-19 vaccine, a long-awaited development for the Maryland company, which has struggled to bring its doses for use in the global inoculation campaign.Shares of Novavax rose about 11 per cent before the opening bell after the company also said it had filed an application for emergency use for the vaccine to Canada as well as the European Medicines Agency.
The Novavax shot was shown to be more than 90 per cent effective, including against a variety of concerning variants of the coronavirus in a large, late-stage U.S.-based clinical trial, with no reports of rare blood clot or heart inflammation issues.